Abstract This was a prospective, multicenter study designed to evaluate the utility of MDCT in the diagnosis of coronary artery disease (CAD) in patients scheduled for elective coronary angiography (CA) using different MDCT systems from different manufacturers. 
of MDCT system (≥16 slices) and compared with quantitative CA performed within 2 weeks of MDCT. A total of 284 patients (81%) were studied by 16-slice MDCT systems, while 66 patients (19%) by 64-slice MDCT scanners. The primary analysis was on-site/off-site evaluation of the negative predictive value (NPV) on a per-patient basis. Secondary analyses included on-site evaluation on a perartery and per-segment basis. On-site evaluation included 327 patients (CAD prevalence 58%). NPV, positive predictive value (PPV), sensitivity, specificity, and diagnostic accuracy (DA) were 0.91 (95% CI 0.85-0.95), 0.91 (95% CI 0.86-0.95), 0.94 (95% CI 0.89-0.97), 0.88 (95% CI 0.81-0.93), and 0.91 (95% CI 0.88-0.94), respectively. Off-site analysis included 295 patients (CAD prevalence 56%). NPV, PPV, sensitivity, specificity, and DA were 0.73 (95% CI
Introduction
Coronary angiography (CA) represents the standard of reference to assess epicardial vessels and establish the presence of significant coronary artery disease (CAD). CA is a bi-dimensional diagnostic technique that allows evaluation of the vessel lumen [1] at high spatial (50 lps/cm) and temporal (<20 ms) resolution. However, CA has its limitations: it is an invasive technique, involves high costs, requires hospitalization, and has low patient compliance. The risks associated with CA are related to its invasiveness and result in a morbidity rate of 1.5% and a mortality rate of 0.15% [2] . In addition, a considerable proportion of patients undergoing CA are subsequently found not to have clinically significant disease [3, 4] . These limitations may justify the increasing clinical use of alternative non-invasive imaging techniques for the evaluation and exclusion of clinically significant CAD.
Many centers have reported their experiences in using different multidetector computed tomography (MDCT) technologies, all of which have been characterized by high diagnostic accuracy in the assessment of patients scheduled for CA. Whether the reported diagnostic accuracy can be replicated in clinical practice needs to be established at different centers with varying expertise, in non-selected patient populations and with different MDCT systems before extensive clinical application of MDCT for CAD assessment.
The primary aim of this study was to assess the negative predective value (NPV) of MDCT in a multicenter study using different MDCT machines/manufacturers to determine if the technique could replace an invasive procedure to exclude the presence of significant CAD. Secondary objectives were to investigate whether MDCT performance is affected by patient characteristics such as pre-test CAD risk, body mass index (BMI), and coronary artery calcium score (CACS). Safety was also investigated.
Materials and methods
This was a national, multicenter, prospective trial sponsored by the Italian Society of Medical Radiology (SIRM).
Adult patients previously scheduled for an elective CA evaluation for a diagnostic workup at each of the participating centers were consecutively evaluated for inclusion in the study. Exclusion criteria included pregnancy or lactation, contraindication to intravenous administration of iodinated contrast media, heart rate >70 beats per minute (bpm) despite beta-blocker treatment, absence of sinus rhythm, New York Heart Association (NYHA) class III-IV, previous coronary artery bypass graft surgery (CABG) or stenting, and creatinine value >2 mg/dl. The Institutional Review Boards of all centers approved the study protocol, and written informed consent was obtained from all patients before study inclusion in accordance with the national legislation and the Declaration of Helsinki.
Patient preparation
Patients with heart rates >70 bpm were given an oral dose of metoprolol tartrate 45-60 min before MDCT imaging or an intravenous beta-receptor blocker just before the scan. Heart rate, electrocardiogram (ECG), and blood pressure were monitored.
MDCT protocol and image reconstructions
Patients underwent 16-or 64-slice MDCT with a standardized and optimized protocol for each type of CT machine. Unenhanced prospective ECG-gated MDCT was performed for the assessment of calcium deposits by Agatston Score (AS). A bolus of 100-120 ml of non-ionic iodinated contrast medium Ultravist® (Iopromide 370; Bayer Schering Pharma, Berlin, Germany) was intravenously injected, preferably through the right antecubital vein, at a flow rate of 3-4 ml/s for the 16-slice MDCT system and 4-6 ml/s for the 64-slice MDCT system, and followed by a 40-50-ml saline chaser at the same flow rate.
The main scan parameters have been given for each scanner type in Table 1 , including the number of patients scanned on each CT system. All images were reconstructed in all phases of the entire cardiac cycle, by means of retrospective synchronization with the ECG track, expressed as a percentage of the R-R interval (relative delay) or as absolute temporal distance (ms) before the next R wave.
MDCT angiographic analysis MDCT angiograms were analyzed both on-site and off-site. The on-site analysis was conducted by a single radiologist at each center who was aware of the patient's clinical condition, but blinded to the results of the invasive CA. Among the data sets reconstructed at several phases of the cardiac cycle, the three with the best image quality were saved on CD and sent for centralized off-site evaluation that was performed by two independent radiologists with proven experience in cardiac CT imaging, but who were not involved in the clinical study and who were blinded to any patient-related information. Any disagreement between off-site readers was resolved by consensus. An evaluating form with coronary arteries segmented according to the guidelines of the American Heart Association (AHA) [5] was used for both analyses. Lesions were classified by the maximal luminal diameter stenosis by qualitative analysis of the most severe well-defined lesion in each segment. Segments were classified as normal (smooth, parallel, or tapering borders), as non-significant disease (luminal irregularities or <50% lumen reduction), as significant stenoses (lumen reduction between 50% and 99%), or occluded. In the case of multiple lesions in a given segment, the segment was classified by the worst lesion. In the case of multiple abnormal segments per artery, the vessel was classified by the worst segment. Patients were classified as positive for the presence of significant CAD if there was at least one stenosis >50%.
Invasive angiographic analysis
CA was performed by standard techniques within 2 weeks after MDCT procedure, using a transfemoral or transradial technique. CA was evaluated on-site by a single experienced cardiologist blinded to the MDCT findings. Segmental disease was analyzed in each vessel using the same 15-segment model and form employed for MDCT analysis. Stenosis severity in each segment was classified according to the maximal luminal diameter stenosis present in each segment. Lesions were examined in orthogonal views and stenosis severity quantitatively determined using an automated edge detection system (quantitative CA, QCA).
Data analysis
The assessment of MDCT accuracy was performed according to a per-patient on-site and off-site evaluation; an on-site artery-and segment-based approach analysis was also performed.
The per-patient analysis included all eligible patients, except those negative at MDCT with at least one of the following segments not assessable at MDCT : 1, 2, 3, 5, 6, 7, 8, 9, 11, and 13 . A patient was classified as true positive if at least one significant coronary stenosis (>50% or occlusion) detected by both modalities was present, regardless of location; a patient was considered as true negative if no significant lesion was found by both modalities.
In the per-artery analysis, segments were combined as right coronary artery (RCA: 1, 2, 3), left main artery (LMA: 5), anterior descending artery (ADA: 6, 7, 8, 9), and circumflex artery (CXA: 11, 13). Arteries deemed negative at MDCT, but with at least one non-assessable segment were excluded. An artery was classified as true positive if at least one significant lesion was detected by both investigations, regardless of location and irrespective of whether or not it was considered for patient inclusion; truenegative arteries appeared normal on all assessable and negative segments.
The per-segment analysis included only segments that were assessable on both investigations. True positives were defined as correct identification by MDCT of significant coronary artery stenosis and true negatives were defined as correct identification by MDCT of segments with stenosis of 50% or less.
Once the concordance of the MDCT with the reference standard had been assessed, the following statistics were calculated: sensitivity, specificity, NPV, positive predictive value (PPV), and diagnostic accuracy (DA).
The primary analysis was the evaluation of the NPVon a per-patient basis, obtained both in on-site and off-site evaluation. Expecting a prevalence of CAD ranging from 0.50 to 0.70, and a specificity of 0.95, the NPV was a Rot. T = rotation time, TR = temporal resolution, ST = slice thickness function of the sensitivity. Since no precise data were available for this parameter, the sample size was calculated in order to obtain a 95% confidence interval for the estimate of sensitivity of not more than 0.1, with the lower limit >0.80. The required number of evaluable patients varied from 254 (prevalence 0.70) to 392 (prevalence 0.50). Anticipating a 10% drop-out rate, it was considered necessary to enroll between 280 and 431 subjects. After the enrollment of about 200 patients, an interim analysis was foreseen in order to obtain a more precise estimate of the prevalence of the disease in the sample studied. Based on the analysis results, a recalculation of the necessary number of subjects was performed. Secondary analyses included the on-site evaluation on a per-artery and per-segment basis. Furthermore, the on-site per-patient analysis was also conducted in subgroups defined by the National Cholesterol Education Program (NCEP) coronary heart disease (CHD) risk (low, intermediate, high) , calcium score (<100, 101-400, 401-1,000, >1,000 AS), and type of MDCT scanner (16-and 64-slice) . A χ 2 test for trend was used to test for differences in the modality results in different subgroups of patients. Secondary analysis also included a safety assessment reporting the occurrence of adverse events. Results are expressed as point estimates and their exact 95% confidence intervals (95% CIs). All p-values are two-tailed. Analyses were carried out using SAS System Version 8.20 (SAS, Cary, NC).
Results
Between July 2004 and June 2006, a total of 367 patients scheduled for elective CA for suspected CAD at 20 Italian centers were screened. Seventeen patients (5%) were subsequently excluded due to: CA erased (n=1), major protocol violation (n=9), temporary MDCT equipment unavailability (n=5), and patient refusal (n=2).The final study sample included 350 eligible patients.
Academic institutions comprised 60% of the centers: 35% were located in northern Italy, 45% in central Italy, and 20% in southern Italy and the islands. Both the type and geographical distribution of the institutions were well distributed and representative of the national situation. Figure 1 shows the trial flow diagram and details of reasons for patient ineligibility. A total of 284 (81%) patients were scanned by a 16-slice MDCT scanner, while the remaining 66 (19%) by a 64-slice MDCT. The characteristics of the 350 eligible patients are summarized in Table 2 .
Per-patient analyses
Results of the per-patient analyses are reported in Table 3 . Out of 295 patients analyzed in the off-site evaluation, 166 had at least one segment with a stenosis >50% by QCA, which translates into a disease prevalence of 56%. NPV of MDCT was 0.73 (95% CI 0.65-0.79) and PPV was 0.93 (95% CI 0.87-0.97). Sensitivity was 0.73 (95% CI 0.65-0.79), specificity was 0.93 (95% CI 0.87-0.97), and DA was 0.82 (95% CI 0.77-0.86).
The on-site evaluation included 327 patients with a CAD prevalence of 58%. NPV of MDCT was 0.91 (95% CI 0.85-0.95), and PPV was 0.91 (95% CI 0.86-0.95). Sensitivity was 0.94 (95% CI 0.89-0.97), specificity was 0.88 (95% CI 0.81-0.93), and DA was 0.91 (95% CI 0.88-0.94).
Evaluating the CHD risk in our population, the prevalence was 0.38 for the low risk, 0. Assessing the influence of BMI on MDCT performance, false-positive results were more frequent in obese patients, specificity fell from 0.92 in normal patients to 0.67 in obese subjects (χ 2 test for trend=6.29; p=0.012). PPV was slightly negatively affected by BMI: 0.92 in normal and 0.76 in obese subjects (χ 2 test for trend=4.00; p=0.046). Nonsignificant differences resulted for sensitivity, NPV, and DA because of a high number of correct negatives (14/21).
The analysis of calcium score effect was performed by collapsing the two higher categories (401-1,000 and >1,000 AS) into one, because of the low number of patients in each category. Specificity significantly (p<0.001) decreased when CACS increased: 0.94 (0-100 AS), 0.76 (101-400 AS), and 0.50 (>400 AS). NPV was negatively affected by increasing CACS: 0.94 (0-100 AS) vs. 0.86 (101-400 AS) vs. 0.62 (>400 AS). No effect on MDCT performance was observed for the type of CT machine.
On-site per-artery analysis
Results of the per-artery analysis are reported in Table 4 . Of the 1,328 arteries analyzed on-site, 296 (22%) had a stenosis >50% by CA. NPV of MDCT was 0.96 (95% CI 0.93-0.98) for RCA, 0.99 (95% CI 0.97-1.00) for LMA, 0.91 (95% CI 0.86-0.95) for ADA, and 0.94 (95% CI 0.90-0.96) for CXA, respectively, with an overall NPV of 0.96 (95% CI 0.94-0.97).
On-site per-segment analysis
Results of the per-segment analysis are reported in Table 5 . Of 4,628 segments analyzed on-site, 530 (11%) had a stenosis >50% by CA. The assessable segments were 3,746 (77.59%) by using the 16-slice MDCT system and 882 (78.61%) by using the 64-slice MDCT machine. NPV of MDCT was 0.96 (95% CI 0.95-0.97), and PPV was 0.72 (95% CI 0.68-0.76). Sensitivity was 0.70 (95% CI 0.66-0.74), specificity was 0.96 (95% CI 0.96-0.97), and DA was 0.93 (95% CI 0.93-0.94).
The overall image quality resulted in good (moderate and/or excellent) in 4,292 (93.95%) segments in the on-site analysis and in 3,396 (80.17%) segments in the off-site analysis.
Safety
Six adverse events related to MDCT occurred in 6/350 patients (1.7%): four cases of cutaneous rash, one case of vomiting, and one case of nausea. All cases were related to contrast medium injection, all completely recovered, and none was considered serious.
Discussion
Since the first reports [7, 8] , MDCT has been characterized by continuous and rapid technical evolution, making it possible to examine the heart and the whole course of coronary arteries reliably within a single breath-hold, within a few heart beats, and with sub-millimeter spatial resolution. Many single-center experiences have been reported [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] using different MDCT technologies, most of which have been characterized by high values of DA in the assessment of patients scheduled for CA [9-18; 20-28] . On a per-patient basis, the average weighted sensitivity reported in these series for the detection of at least one coronary artery with >50% lumen stenosis is 94% (range 75% to 100%), whereas the average specificity is 77% (range 49% to 100%) [29] [30] . In most of these studies using 16-slice MDCT, up to 23% of coronary segments were considered not assessable [19] ; similarly, data analysis from 64-slice MDCT studies could not be Median (range) BMI = Body mass index; SBP = systolic blood pressure; DBP = diastolic blood pressure; HR = heart rate; NCEP = National Cholesterol Education Program; CHD = coronary heart disease performed in all coronary segments, with a reported percentage of non-assessable segments of up to 12% [22, [26] [27] [28] . In a recent meta-analysis [31] , it was demonstrated that NPV was sufficiently high with 16-section CT (92%), making this an excellent tool to rule out CAD, strengthening our choice to include centers with CT technology ≥16-slice MDCT. Before extensive clinical application of MDCT for CAD assessment can be advocated, it is necessary to establish whether or not the reported DA can be replicated in clinical practice in different centers with varying expertise and MDCT manufacturer. In fact, the main limitations of the current data are the strict eligibility criteria used for patient selection, the restriction of high image-quality data sets to selected cohorts or subgroups of patients, and the predominance of a single MDCT manufacturer. We conducted a prospective national multicenter study, reflecting the technical aspects of different MDCT systems (≥16-slice MDCT) available in Italy at the time of the study to determine whether MDCT can replace the invasive procedure in patients scheduled for elective CA in order to To the best of our knowledge, this is the first study in which patients were studied in several independent national centers with different expertise, using different MDCT machines from different manufacturers, with a standardized and optimized CT protocol. Only one similar multicenter study has been published to date [32] . In that report, 187 patients were studied in 11 participating sites, all using the same MDCT manufacturer. All MDCT and CA results were assessed by a single core laboratory in each case. The per-patient approach was characterized by sensitivity, specificity, PPV, and NPV of 75%, 77%, 60%, and 87%, respectively.
The difference between on-site and off-site evaluation in our study could, in part, be explained by the intrinsic characteristics of the latter assessment as well as by the fact that the two off-site readers were completely unaware of the patient's clinical information. It could also be because blinded assessment of each MDCT was performed by using only three data sets considered to be those with the best image quality by the on-site reader. These results were obtained in patients scheduled for elective CA and with a wide spectrum of clinical settings. The on-site specificity was somewhat lower in comparison with most of the published reports [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] . This is because there was a tendency to overestimate the severity of a lesion on CT (resulting in a number of false-positive outcomes) rather than underestimating the lesion severity and thereby "missing" lesions, which may have had serious consequences in a symptomatic patient population.
The clinical worldwide acceptance of MDCT coronary angiography will probably require further technological development to ensure optimal test results and a guiding management of CAD. The extension of MDCT system usage with higher temporal resolution (<100 ms) may extend the application of this technology for the assessment of CAD in a high probability pre-test population with extensive calcifications and without heart rate control [33] [34] [35] [36] . The employment of hybrid PET/MDCT [37] or SPECT/MDCT equipment with image fusion [38] may offer the opportunity for a comprehensive non-invasive evaluation of the presence of CAD and its consequences, both in the coronary arteries and myocardium.
The radiation dose can be considered a limitation of this technique [39] ; however, due to the study design, the dose analysis was not an objective of our study. The most effective method to reduce radiation exposure is the prospective ECG tube modulation (ECG pulsing) [40] . For 64-slice MDCT, this has been reported to be 14.8±1.8 mSv and 9.4±1.0 mSv without and with ECG-triggering tube output modulation, respectively, and for 16-slice MDCT, 10.6±1.2 mSv, and 6.4±0.9 mSv without and with ECG triggering tube output modulation, respectively [41] .
Leading single center experience, with limited and selected patient populations often including patients who had previously undergone angiography, may be difficult to translate into general clinical practice. The multicenter study reported here should reflect the clinical value of MDCT coronary angiography more accurately, because a larger number of patients at different national centers has been evaluated using all the principal MDCT manufacturers, thus reflecting real-world clinical practice. The high NPV observed suggests that ECG-gated MDCT coronary angiography could be useful to discriminate those patients who really need an invasive CA, ruling out clinically significant CAD in patients amongst whom the prevalence of disease is low or intermediate [42] and in patients with an equivocal stress test, as recently recommended also by the Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology [43] . However, to ensure that this non-invasive test is more accurate, it is important to combine MDCT findings with accurate and complete patient clinical information.
Funding The study was sponsored by the Italian Society of Medical Radiology (SIRM), with the support of Bayer Schering Pharma, Bayer spa, Milan, Italy 
Conflict of Interest None declared

